Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

40,991 stories, page 431 of 684

Advanced search

🌍Jul 24discoverynews.google.comTier 2 · Trade media

Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout

Fierce BiotechOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers

Hot Springs Sentinel RecordOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

CSPC Pharmaceutical Group's Stock Price Soars to 8.55 HKD, Marking a Robust 2.15% Increase

SmartkarmaOriginal source

🌍Jul 24discoverynews.google.comTier 2 · Trade media

The U.S. pharmaceutical supply chain problem is not about China

STATOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Chugai Pharmaceutical Co., Ltd. 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:CHGCY) 2026-07-24

Seeking AlphaOriginal source

🌍Jul 24Medianovartis.comTier 3 · Secondary coverage

How Novartis R&D is advancing the next breakthrough innovations

NovartisOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Chugai Pharmaceutical (4519) Q2 2026 earnings summary

QuartrOriginal source

🌍Jul 24discoverynews.google.comTier 2 · Trade media

Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds

Fierce BiotechOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

The Hybrid Vaccine Trial Design That Could Render Pure RCTs Obsolete

The Clinical Trial VanguardOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Atika Capital Management LLC

MarketBeatOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Bank of New York Mellon Corp Decreases Stake in Teva Pharmaceutical Industries Ltd. $TEVA

MarketBeatOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Almirall builds on biologics as first-half earnings climb

The Pharma LetterOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

GC Biopharma Files for Phase 2 Trial of Korean-Made mRNA COVID-19 Vaccine, Aiming for August Start

finance.biggo.comOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Radiopharm Theranostics Raises A$12.5 Million in Institutional Capital as RAD101 Phase 3 Trial Nears Commencement

KalkineOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Chugai Pharmaceutical : First-half FY2026 revenue rose 14.7% and core net income increased 23.2% year-over-year

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Celltrion Files for European Phase 3 Trial of Zymfentra for Rheumatoid Arthritis

Seoul Economic DailyOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Chugai Pharmaceutical : Double-digit revenue and profit growth driven by strong sales and robust pipeline progress

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406

Macau BusinessOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Laminar Pharma Completes LAM561 Phase 2b/3 Trial in Glioblastoma

The Clinical Trial VanguardOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Atsena Gets EMA Orphan Status for ATSN-101 and ATSN-201

The Clinical Trial VanguardOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Johnson & Johnson reports positive data from clinical trial of bone marrow cancer treatment

medwatch.comOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Genmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpoint

The Clinical Trial VanguardOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

GC Biopharma files phase 2 IND for Covid-19 mRNA vaccine candidate

koreabiomed.comOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

GC Biopharma files phase 2 IND for Covid-19 mRNA vaccine candidate

koreabiomed.comOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

GC Green Cross Files for Phase 2 Trial of Domestic mRNA Vaccine

Seoul Economic DailyOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

BB Biotech (BION) Q2 2026 earnings summary

QuartrOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership

Yahoo FinanceOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Always Learn: Philip Ashton-Rickardt on Building a Biotech Career Without a Blueprint

WBOC TVOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Dong-A Socio to absorb pharmaceutical unit

매일경제Original source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

BB Biotech Reports Net Profit Of CHF 451 Mln In Q2 2026

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Atai Beckley's Takeover Math: Why the Stock Is Outrunning the Cash Offer

AD HOC NEWSOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

BB Biotech AG publishes its interim report and revises its dividend policy

marketscreener.comOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

BB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioning

marketscreener.comOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:WST) 2026-07-24

Seeking AlphaOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

BB Biotech AG publishes its interim report and revises its dividend policy

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

BB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioning

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Enterprise value to EBITDA forward of Egyptian International Pharmaceutical Industries Co. – EGX:PHAR

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Hanmi showcases AI platform behind clinical-stage obesity drug at ISMB

koreabiomed.comOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

[News Analysis] Kolon faces leadership test after TG-C's first US phase 3 setback

koreabiomed.comOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

〔Stocks to Watch〕Pharmaceutical stocks rose, supported by buying in defensive names and front-running purchases ahead of earnings announcements.

MoomooOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

World Pharmaceutical Grade Hyaluronic Acid - Market Analysis, Forecast, Size, Trends and Insights

IndexBoxOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Enterprise value to EBIT forward of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A – SZSE:002399

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Price to sales forward of Egyptian International Pharmaceutical Industries Co. – EGX:PHAR

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Cardiovascular disease biotech Scribe Therapeutics prices upsized IPO at $15, the high end of the range

renaissancecapital.comOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

FDA Roundup H1 2026: Hematology Drug Alerts

Hematology AdvisorOriginal source

🇺🇸Jul 24Regulatoryfda.govTier 1 · Regulatory source

BAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTION

July 24, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling Lot L...

FDA MedWatchOriginal source

🇺🇸Jul 24Regulatoryfda.govTier 1 · Regulatory source

Early Alert: Percutaneous Catheter Issue from Boston Scientific

ENROUTE Transcarotid Neuroprotection Systems may have arterial sheath tip separation or partial tip...

FDA MedWatchOriginal source

🇺🇸Jul 24Industryir.codexis.comTier 1 · Company source

Codexis Announces Pricing of Public Offering of Common Stock

CodexisOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Price to earnings forward of Guizhou Bailing Group Pharmaceutical Co., Ltd. Class A – SZSE:002424

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Korea, Europe partner on AI, green biotech for future farming

The Korea TimesOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

FDA panel recommends loosening restrictions on peptides, despite scientists’ concerns

The Washington PostOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services Q2 Earnings Call Highlights

Yahoo FinanceOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

'Not scientifically supportable:' Inside FDA’s refusal to face US generic drug crisis

wtvcfoxOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns

CNBCOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Dong-A Socio Holdings to absorb Dong-A Pharmaceutical, become operating holding company

koreabiomed.comOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

'Not scientifically supportable:' Inside FDA’s refusal to face US generic drug crisis

WLOSOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

US health panel loosens restrictions for controversial peptides popular online

BBCOriginal source

🌍Jul 24discoverynews.google.comTier 2 · Trade media

Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing

Endpoints NewsOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406

The Malaysian ReserveOriginal source

🌍Jul 24discoverynews.google.comTier 2 · Trade media

Scribe secures $129M in a rare gene editing IPO

BioPharma DiveOriginal source